This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.
Novartis has announced that it has received approval from the US Food and Drug Administration (FDA) for Pluvicto for the treatment of adult patients with advanced prostate cancer. ... Prostate cancer is the second leading cause of cancer-related death in
early detection of lung and prostate cancer. ... EIT Health supports various cancer programmes and start-ups aiming to improve outcomes for lung and prostate cancer patients, including Stockholm3, OncoWatch and Optellum – three programmes using
The other programmes are for etrumadenant, a dual adenosine A2a/A2b receptor antagonist in phase 1/2 studies in NSCLC, colon cancer and prostate cancer, and quemliclustat, a small molecule CD73 ... deliver benefit to patients with some of the most
with paroxysmal nocturnal haemoglobinuria, plus breakthrough therapy designation for Enhertu (trastuzumab deruxtecan) in breast cancer. ... The results include Lynparza in prostate cancer, Imfinzi plus tremelimumab in liver cancer and biliary tract cancer
New data show AstraZeneca and Merck‘s PARP inhibitor, Lynparza, delayed disease progression as a first-line treatment in advanced prostate cancer. ... Last year, they entered the prostate cancer setting with the approval of Clovis’ Rubraca (rucaparib)
Amgen’s BiTEs work by attaching themselves to both a cancer cell and T cell, bringing them together so the body’s immune system can kill the cancer. ... TNB-585 is a bispecific T cell-engager being evaluated for the treatment of metastatic
More from news
Approximately 69 fully matching, plus 307 partially matching documents found.
continuum of targeted therapies now available to prostate cancer patients, including PARP inhibitors. ... Similarly, DRD testing in late stage prostate cancer is needed to identify patients who could potentially benefit from PARP inhibition.
Be it treatment for cancer, aches and pains, unusual lumps, headaches – the general malay that you would visit your doctor or hospital for consultation and treatment. ... Nudge behaviour, such as timely reminders for breast or prostate cancer screening,
your patients a disservice while you’re at it). We’ve been acutely aware of this balancing act in our own work; a recent film we worked on for prostate cancer ... With this as our starting point, we introduced messaging about the importance of
the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying
This treatment quickly became the ‘gold standard’ for women with metastatic breast cancer. ... In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon
More from intelligence
Approximately 1 fully matching, plus 53 partially matching documents found.
Levy, a published author of research into the needs of men with advanced prostate cancer, also brings over ten years of experience in the healthcare sector to the team.
urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.
breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
In a month focused on raising awareness of Black history and prostate cancer, Che’s life experiences are pertinent and valuable. ... These include growing up as the only Black kid in his school, socialising with groups with opposing views to his own,
According to research , men are more likely to die six years earlier than women due to :. - Mental health. - Prostate cancer. - Testicular cancer. What are the causes for that?
This Black History Month, we discuss the black representation in clinical trials and the effects COVID-19 has had on the black community. Innovative Trials are passionate about ensuring our diverse population is adequately represented within medical
10. This includes:. Supporting research efforts for male-specific diseases such as prostate and testicular cancer.
These are self-contained, disease and condition specific educational resources for topics including stroke prevention, transplantation and prostate cancer.
More from PMHub
Approximately 6 fully matching, plus 20 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...